ECPG vs REGN · P/E 6.3, rev $1.32B vs P/E 14, rev $14.34B
Encore Capital Group Inc (ECPG) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Encore Capital Group Inc (ECPG) is a credit services company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ECPG revenue for 2024-12-31 was $1.32B. Net income was -$139.2M. Revenue was up 7.7% from 2023-12-31 to 2024-12-31. ECPG currently screens at market cap $1.73B and trailing P/E 6.3.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ECPG currently screens at market cap $1.73B and trailing P/E 6.3. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ECPG and REGN stock pages for the full models.
Not investment advice.